In 2025, children aged 5-14 are experiencing the highest number of dengue cases, with severe outbreaks reported among school-aged children*. These outbreaks are projected to be three times higher than the five-year average.*

The new 2-dose, 4-serotype dengue vaccine can help prevent infection or reduce the severity of symptoms of infection.

Vaccine effectiveness**

• 80.2% protection against dengue infection
• 90.4% fewer hospitalizations

Who Can Get the Dengue Vaccine?

• Recommended for children aged 4 and above
• Requires 2 doses, administered 3 months apart

Can children who have had dengue before get vaccinated?

• The vaccine is suitable for children whether or not they have a prior history of dengue fever; no blood test is required for eligibility.
• The vaccine should not be used in pregnant women, breastfeeding women, or individuals with severe immune deficiency.
• Those who have had dengue should wait at least 6 months after recovery before receiving the vaccine.
• For travelers from non-endemic countries who are visiting dengue-endemic areas like Thailand for extended periods (4 weeks or more), the 2-dose vaccine may be considered. The first dose should be administered at least 14 days before travel, followed by the second dose 3 months later.

• How many years does the dengue vaccine last in children?

• Achieves maximum immunity in 4 weeks. Immunity lasts at least 4.5 years after the administration of the 2nd dose. (Source: Supplementary Fig. S3. Lancet Glob Health (2024); 12: e257–70)
• *Source: Bureau of Epidemiology / Risk Communication Office, Department of Disease Control (January 10, 2024)
  **Vaccine effectiveness is based on individuals without underlying conditions or deficient immune function